Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
3.03 EUR
13.50 B EUR
38.82 B EUR
3.16 B
About NOVO NORDISK B A/S
Sector
Industry
CEO
Lars Fruergaard Jørgensen
Website
Headquarters
Bagsværd
Founded
1931
ISIN
DK0062498333
FIGI
BBG000DYN870
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
NVO absolutely sweet levelThis downturn is attributed to disappointing clinical trial results for some of its drugs and concerns over potential tariffs affecting Denmark. Additionally, competition from Eli Lilly's successful weight-loss drug trials has impacted investor confidence.
Despite these challenges, analysts note
$NVO offers solid risk to reward for long term buyers! - I had previously called out that NYSE:NVO would have more pain to come when it was in $85-90s I have attached the link with this post for my reader's reference.
- Now, I am turning bullish on this name given these prices and compressed multiples for the growth prospects it offers.
Fundamenta
Novo Nordisk's The recent drop in Novo Nordisk's stock price is attributed to several factors. A key issue is the company’s struggle to meet the surging demand for its weight-loss drugs, such as Wegovy. Although demand remains strong, investors are concerned about Novo Nordisk's ability to scale up production and
NVO: Oversold, But I’m Staying PatientYes, NVO has pulled back hard — from highs near $148 to the mid-$60s, now trading around $68.33. While this selloff may look oversold on many levels, I’m still avoiding the stock for now.
The broader market remains in a downtrend, and with macro uncertainty still front and center, I’m not eager to
NVO, Rhyming with historical golden buy zoneUsing the Guassian Channel indicator on the monthly timeframe. We can see that in the past, after the price has significantly correct from its ATH of 50%+, price tend to reverse at the lower channel support(2times on chart) or at the upper support line ( 1 time on the chart)
Right now we are curre
3/27/25 - $nvo - obvious at $70... 10% size3/27/25 :: VROCKSTAR :: NYSE:NVO
obvious at $70... 10% size
- at btc conf in miami so have been hoping for a quiet week. well. whatever. another day in trumptopia. but alas, we can't tell the market what we want. so the game today is just don't make big mistakes and try and find interesting asymm
Novo Nordisk: 50% Drops Lead to Amazing GrowthFundamentals :
Take a look at NVO in 1999-2000, 2003, 2008, 2016 and June 20024-2025. Every time it dropped about 50%, that lead to a huge rally for years! NVO has secured contracts with Medicaid for their diabetes and other drugs. It is not going anywhere. It has fallen 50%. We either hold or buy
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where NOV is featured.
Related stocks
Frequently Asked Questions
The current price of NOV is 54.72 EUR — it has decreased by −0.69% in the past 24 hours. Watch NOVO-NORDISK AS B DK 0,1 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange NOVO-NORDISK AS B DK 0,1 stocks are traded under the ticker NOV.
NOV stock has fallen by −2.79% compared to the previous week, the month change is a −20.66% fall, over the last year NOVO-NORDISK AS B DK 0,1 has showed a −53.51% decrease.
We've gathered analysts' opinions on NOVO-NORDISK AS B DK 0,1 future price: according to them, NOV price has a max estimate of 153.65 EUR and a min estimate of 46.76 EUR. Watch NOV chart and read a more detailed NOVO-NORDISK AS B DK 0,1 stock forecast: see what analysts think of NOVO-NORDISK AS B DK 0,1 and suggest that you do with its stocks.
NOV stock is 5.25% volatile and has beta coefficient of 1.42. Track NOVO-NORDISK AS B DK 0,1 stock price on the chart and check out the list of the most volatile stocks — is NOVO-NORDISK AS B DK 0,1 there?
Today NOVO-NORDISK AS B DK 0,1 has the market capitalization of 239.31 B, it has increased by 0.27% over the last week.
Yes, you can track NOVO-NORDISK AS B DK 0,1 financials in yearly and quarterly reports right on TradingView.
NOVO-NORDISK AS B DK 0,1 is going to release the next earnings report on May 7, 2025. Keep track of upcoming events with our Earnings Calendar.
NOV earnings for the last quarter are 0.85 EUR per share, whereas the estimation was 0.80 EUR resulting in a 6.08% surprise. The estimated earnings for the next quarter are 0.82 EUR per share. See more details about NOVO-NORDISK AS B DK 0,1 earnings.
NOVO-NORDISK AS B DK 0,1 revenue for the last quarter amounts to 11.46 B EUR, despite the estimated figure of 10.71 B EUR. In the next quarter, revenue is expected to reach 10.46 B EUR.
NOV net income for the last quarter is 3.77 B EUR, while the quarter before that showed 3.66 B EUR of net income which accounts for 3.14% change. Track more NOVO-NORDISK AS B DK 0,1 financial stats to get the full picture.
NOVO-NORDISK AS B DK 0,1 dividend yield was 1.83% in 2024, and payout ratio reached 50.28%. The year before the numbers were 1.35% and 50.35% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Apr 27, 2025, the company has 76.3 K employees. See our rating of the largest employees — is NOVO-NORDISK AS B DK 0,1 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NOVO-NORDISK AS B DK 0,1 EBITDA is 19.99 B EUR, and current EBITDA margin is 50.95%. See more stats in NOVO-NORDISK AS B DK 0,1 financial statements.
Like other stocks, NOV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NOVO-NORDISK AS B DK 0,1 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NOVO-NORDISK AS B DK 0,1 technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NOVO-NORDISK AS B DK 0,1 stock shows the sell signal. See more of NOVO-NORDISK AS B DK 0,1 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.